---
title: 'Plain language summary of the results from the TALAPRO-2 study: Talazoparib
  plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate
  cancer'
date: '2024-07-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38995237/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240712181613&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'WHAT IS THIS SUMMARY ABOUT?: This summary describes the results from
  the TALAPRO-2 research study (also known as a clinical trial). The TALAPRO-2 study
  tested the combination of two medicines called talazoparib plus enzalutamide. This
  combination of medicines was used as the first treatment for adult patients with
  metastatic castration-resistant prostate cancer. The combination of talazoparib
  plus enzalutamide was compared with a placebo plus ...'
disable_comments: true
---
WHAT IS THIS SUMMARY ABOUT?: This summary describes the results from the TALAPRO-2 research study (also known as a clinical trial). The TALAPRO-2 study tested the combination of two medicines called talazoparib plus enzalutamide. This combination of medicines was used as the first treatment for adult patients with metastatic castration-resistant prostate cancer. The combination of talazoparib plus enzalutamide was compared with a placebo plus ...